Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (281) Arrow Down
Filter Results: (281) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (417)
    • News  (88)
    • Research  (281)
    • Events  (1)
    • Multimedia  (4)
  • Faculty Publications  (96)

Show Results For

  • All HBS Web  (417)
    • News  (88)
    • Research  (281)
    • Events  (1)
    • Multimedia  (4)
  • Faculty Publications  (96)
← Page 4 of 281 Results →
Sort by

Are you looking for?

→Search All HBS Web
  • September 1991 (Revised February 1993)
  • Case

Burroughs Wellcome and AZT (A)

By: Willis M. Emmons III
Burroughs Wellcome Co., developer of AZT, the first drug approved by the U.S. Food and Drug Administration for the treatment of Acquired Immune Deficiency Syndrome (AIDS), finds itself under siege in September 1989 by AIDS activists and various segments of the U.S.... View Details
Keywords: Governing Rules, Regulations, and Reforms; Ethics; Business and Government Relations; Communication Strategy; Health Care and Treatment; Monopoly; Intellectual Property; Research and Development; Price; Pharmaceutical Industry; London
Citation
Educators
Purchase
Related
Emmons, Willis M., III. "Burroughs Wellcome and AZT (A)." Harvard Business School Case 792-004, September 1991. (Revised February 1993.)
  • November 2008 (Revised July 2009)
  • Background Note

A Managerial Perspective on Clinical Trials

By: Arthur A. Daemmrich
This note describes the history and regulation of clinical trials, managerial challenges related to pharmaceutical product testing, and current debates regarding prescription drug safety. Since clinical testing takes between five and seven years, and consumes up to 70... View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Testing and Trials; Product Development; Safety; Biotechnology Industry; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Daemmrich, Arthur A. "A Managerial Perspective on Clinical Trials." Harvard Business School Background Note 709-033, November 2008. (Revised July 2009.)
  • August 2001
  • Case

Pharmaceutical Industry and the AIDS Crisis in Developing Countries, The

Explores the controversy over the pricing of AIDS drugs in poor countries. This issue has received wide publicity due to two events: 1) a court case in South Africa that seeks to force drug companies to license their patents and 2) the announcement by the Indian... View Details
Keywords: Competition; Developing Countries and Economies; Business and Government Relations; Pharmaceutical Industry; South Africa; India
Citation
Educators
Purchase
Related
Kennedy, Robert E. "Pharmaceutical Industry and the AIDS Crisis in Developing Countries, The." Harvard Business School Case 702-010, August 2001.
  • December 1999 (Revised February 2001)
  • Case

CVS: The Web Strategy

By: John A. Deighton and Anjali C. Shah
How should America's second-largest pharmacy chain respond to the challenge from online drugstores? What threat does the web pose to bricks and mortar distribution of prescription drugs and the other items that make up 50% of a drugstore's sales? This case describes... View Details
Keywords: Leveraged Buyouts; Marketing Channels; Distribution Channels; Service Operations; Corporate Strategy; Pharmaceutical Industry; Web Services Industry
Citation
Educators
Purchase
Related
Deighton, John A., and Anjali C. Shah. "CVS: The Web Strategy." Harvard Business School Case 500-008, December 1999. (Revised February 2001.) (request a courtesy copy.)
  • September 2014 (Revised February 2015)
  • Case

Pfizer and AstraZeneca: Marketing an Acquisition (A)

By: John A. Quelch and James Weber
In 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced difficulties in growing sales due to... View Details
Keywords: Health Care Policy; Mergers And Acquisitions; Marketing; Government Relations; Crisis Management; Decision Making; Growth and Development; Management; Markets; Strategy; Pharmaceutical Industry; United Kingdom; United States
Citation
Educators
Purchase
Related
Quelch, John A., and James Weber. "Pfizer and AstraZeneca: Marketing an Acquisition (A)." Harvard Business School Case 515-007, September 2014. (Revised February 2015.)
  • January 1995 (Revised March 1997)
  • Case

A Bankruptcy Problem from the Talmud

Describes a problem of bankruptcy, following the treatment in the 2,000-year-old Babylonian Talmud. A person dies, leaving a number of debts that total more than the size of the estate. The question is: How should the estate be divided among the creditors? The case... View Details
Keywords: Analysis; Insolvency and Bankruptcy; Economics
Citation
Educators
Purchase
Related
Brandenburger, Adam M., Harborne W. Stuart Jr., and Barry Nalebuff. "A Bankruptcy Problem from the Talmud." Harvard Business School Case 795-087, January 1995. (Revised March 1997.)
  • August 2004 (Revised July 2006)
  • Case

PROPECIA TM: Helping Make Hair Loss History

By: Marta Wosinska and Youngme E. Moon
In late 1997, Tom Casola, brand manager for Propecia, debates the best approach to market this breakthrough one-a-day pill for hair loss. This launch would be atypical for a prescription drug because of the key position of the consumer. As a result, the team's... View Details
Keywords: Advertising; Communication Strategy; Customers; Marketing Communications; Marketing Strategy; Product Launch; Product; Performance Effectiveness; Problems and Challenges; Quality; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Wosinska, Marta, and Youngme E. Moon. "PROPECIA TM: Helping Make Hair Loss History." Harvard Business School Case 505-035, August 2004. (Revised July 2006.)
  • March 2014
  • Editorial

Limits on Use of Health Economic Assessments for Rare Diseases

By: Hanna I. Hyry, Ariel Dora Stern, Jonathan CP Roos and Timothy M. Cox
Funding of expensive treatments for rare ('orphan') diseases is contentious. These agents fare poorly on 'efficiency' or health economic measures, such as the QALY, because of high cost and frequently poor gains in quality of life and survival. We show that... View Details
Keywords: Cost; Health Disorders; Health Care and Treatment; Pharmaceutical Industry
Citation
Find at Harvard
Related
Hyry, Hanna I., Ariel Dora Stern, Jonathan CP Roos, and Timothy M. Cox. "Limits on Use of Health Economic Assessments for Rare Diseases." hcu016. QJM: An International Journal of Medicine 107, no. 3 (March 2014): 241–245.
  • 31 Oct 2004
  • Research & Ideas

Bypass Marketing: Are Docs Influenced?

Until the close of the last decade, health consumers received much of their knowledge and advice about prescription drugs from their physicians or other health care professionals. Today, pharmaceutical... View Details
Keywords: by Manda Salls
  • Article

How to Avoid Executive Stress

By: Thomas J. DeLong
When teaching various groups of executives, the author relates the story of a man addicted to prescription drugs and his brother who is addicted to achievement. Each group relates to these two professionally successful men and sees that they live largely on the edge of... View Details
Keywords: Behavior; Personal Development and Career; Personal Characteristics; Emotions
Citation
Related
DeLong, Thomas J. "How to Avoid Executive Stress." Market Leader (Second Quarter 2012), 50–52.
  • 12 Jul 2016
  • First Look

July 12, 2016

of Biosimilars: Evidence from Europe By: Scott Morton, Fiona, Ariel Dora Stern, and Scott Stern Abstract—Biologic (large-molecule) drugs represent a disproportionate and growing share of all drug spending in... View Details
Keywords: Sean Silverthorne
  • May 2017
  • Article

When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization

By: Leemore S. Dafny, Christopher Ody and Matt Schmitt
Branded pharmaceutical manufacturers frequently offer “copay coupons” that insulate consumers from cost sharing, thereby undermining insurers’ ability to influence drug utilization. We study the impact of copay coupons on branded drugs first facing generic entry... View Details
Keywords: Brands and Branding; Insurance Industry; Pharmaceutical Industry
Citation
Find at Harvard
Read Now
Related
Dafny, Leemore S., Christopher Ody, and Matt Schmitt. "When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization." American Economic Journal: Economic Policy 9, no. 2 (May 2017): 91–123.
  • Article

Overturning the ACA's Medicaid Expansion Would Likely Decrease Low-Income, Reproductive-Age Women's Healthcare Spending and Utilization

By: Lucy Chen, Richard G. Frank and Haiden A. Huskamp
In late 2020, the Supreme Court began hearing a case challenging the Affordable Care Act (ACA), which led to coverage gains for many low-income, reproductive-age women. To explore potential implications of a full ACA repeal for this population, we examined gains... View Details
Keywords: Medicaid; Women's Health; Health Insurance; Health Care and Treatment; Gender; Insurance; Poverty; Health Industry; United States
Citation
Read Now
Related
Chen, Lucy, Richard G. Frank, and Haiden A. Huskamp. "Overturning the ACA's Medicaid Expansion Would Likely Decrease Low-Income, Reproductive-Age Women's Healthcare Spending and Utilization." Inquiry 57 (2020).
  • March 2024
  • Article

Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act

By: Matthew Vogel, Pragya Kakani, Amitabh Chandra and Rena M. Conti
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary sources to apply the IRA's negotiation criteria retrospectively, we identify all drugs that... View Details
Keywords: Policy; Government Legislation; Health Care and Treatment; Negotiation; Price; Pharmaceutical Industry
Citation
Find at Harvard
Purchase
Related
Vogel, Matthew, Pragya Kakani, Amitabh Chandra, and Rena M. Conti. "Medicare Price Negotiation and Pharmaceutical Innovation Following the Inflation Reduction Act." Nature Biotechnology 42, no. 3 (March 2024): 406–412.
  • 10 Aug 2015
  • Research & Ideas

New Medical Devices Get To Patients Too Slowly

While the US Food and Drug Administration has chiseled away pharmaceutical review times over the years to speed innovative drugs to market, the opposite seems to have occurred in the agency's approval of... View Details
Keywords: by Michael Blanding; Health; Technology
  • 26 Jul 2016
  • Working Paper Summaries

The Impact of the Entry of Biosimilars: Evidence from Europe

Keywords: by Fiona Scott Morton, Ariel Dora Stern, and Scott Stern; Health; Biotechnology; Pharmaceutical
  • Working Paper

Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S.

By: Pragya Kakani, Michael Chernew and Amitabh Chandra
Rising list prices are often used to illustrate the burden of prescription drug spending, but payers routinely negotiate rebates from manufacturers that generate differences between list and net prices. List prices are easily available and affect patient cost-sharing,... View Details
Keywords: Pharmaceuticals; Rebates; Health Care and Treatment; Markets; Price; Analysis; Pharmaceutical Industry
Citation
Find at Harvard
Read Now
Related
Kakani, Pragya, Michael Chernew, and Amitabh Chandra. "Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S." NBER Working Paper Series, No. 26846, March 2020.
  • 2006
  • Book

Science Business: The Promise, the Reality, and the Future of Biotech

By: Gary P. Pisano
Why has the biotechnology industry failed to perform up to expectations—despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of the industry. Pisano not only reveals the underlying causes of... View Details
Keywords: Science; Business Ventures; Biotechnology Industry
Citation
Find at Harvard
Purchase
Related
Pisano, Gary P. Science Business: The Promise, the Reality, and the Future of Biotech. Boston: Harvard Business School Press, 2006.
  • 01 Aug 2023
  • Cold Call Podcast

Can Business Transform Primary Health Care Across Africa?

Keywords: Re: Regina E. Herzlinger; Pharmaceutical; Health
  • 2024
  • Article

Effects of a Real-Time Information-Based Intervention on Physician Prescribing Behavior

By: Olivia Zhao and Anna D Sinaiko
High out-of-pocket (OOP) prices for prescription drugs create financial difficulties for patients, and cost-related underuse of medications can adversely patient health. Simultaneously, many physicians report a willingness to address affordability concerns with... View Details
Keywords: Price; Health Care and Treatment; Communication Technology; Technology Adoption; Customer Focus and Relationships; Health Industry
Citation
Register to Read
Related
Zhao, Olivia, and Anna D Sinaiko. "Effects of a Real-Time Information-Based Intervention on Physician Prescribing Behavior." Academy of Management Best Paper Proceedings 2024, no. 1 (2024).
  • ←
  • 4
  • 5
  • …
  • 14
  • 15
  • →

Are you looking for?

→Search All HBS Web
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.